Stage FocusSeed, Series A
GeographyUS
TypeVC
Last Activity2025
Industry Focus
Industries
Synthetic BiologyBiotechMedTech
Technical BenchStrong
Investor TypeDeepTech Purist
ExposureMostly DeepTech Investments
Bio
Newpath Partners was founded in 2018 by Tom Cahill, an MD/PhD physician-scientist who moved into investing. Fund II closed at $350M in December 2021 with a mandate to create life sciences companies, not just fund them.
The firm specializes in breakthrough biology platforms — gene editing and regenerative medicine in particular. The portfolio includes 13 companies, with 2 IPOs and 3 acquisitions (...
Notable Investments
P
Prime MedicineC
Chroma MedicineM
Myeloid TherapeuticsK
Kojin TherapeuticsE
Exo TherapeuticsSimilar Funds
Illumina Ventures
San Diego, United States
Pure DeepTechSynthetic BiologyBiotechMedTechSeedSeries A
The Production Board
San Francisco, United States
Pure DeepTechSynthetic BiologyAgriTechBiotechPre-SeedSeed
Alwyn Capital
Brooklyn, United States
DeepTech NativeSynthetic BiologyBiotechMedTechSeedSeries A
Flagship Pioneering
Cambridge, United States
Pure DeepTechSynthetic BiologyBiotechAgriTechPre-SeedSeed
Northpond Ventures
United States
DeepTech NativeSynthetic BiologyBiotechMedTechSeedSeries A
SOSV
New York, United States
Pure DeepTechSynthetic BiologyClimate TechRoboticsPre-SeedSeed